CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Henan Cancer Hospital

Status and phase

Unknown

Phase 1

Conditions

B-Cell Lymphoma Stage I

Relapsed

Refractory

Treatments

Biological: CD19/CD20 bispecific CAR-T cells

Study type

Interventional

Funder types

Other

Identifiers

NCT03881761

HenanCH CART 2-3

Details and patient eligibility

About

Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma

Full description

CART cell therapy has become the treatment of choice for patients with relapsed/ refractory B cell lymphoma. Currently, CAR-T cells approved for relapsed/refractory B-cell lymphoma are mainly CAR19-T cells. Nearly half of patients who relapse after treatment with CAR19-T cells are caused by tumor cell antigen escape. Dual-target CAR-T cells targeting CD19 and CD20 may reduce the recurrence rate after treatment. This study was to evaluate the efficacy and safety of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma.

Enrollment

50 estimated patients

Sex

All

Ages

17 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

expected lifetime>3 months
CD19/CD20 positive relapsed/refractory B cell lymphoma
KPS>70
at least one measurable lesion according to RECIST 1.1
enough function of hear, liver, kidney and bone marrow
no history of severe allergies
no other history of malignancy
no other diseases that conflict with this regimen
no serious mental illness
patient or family member sign informed consent

Exclusion criteria

Pregnant or lactating women
Severe infectious or viral disease
Active B or C viral hepatitis
Patients who have used large amounts of glucocorticoids or other immunosuppressive agents during the last 4 weeks
participated in other clinical studies in the last 3 months, or have been treated with other gene products
Others not appropriate to participate in this study examined by the investigators